Use of a novel non-steroidal anti-inflammatory drug in the horse.
Abstract: In a two-part cross-over experiment in six ponies, an acute inflammatory reaction was generated by injecting carrageenin solution into subcutaneously-implanted tissue-cages lined with fibrovascular granulation tissue. In each part of the cross-over, half of the ponies received a novel phenylpyrazoline anti-inflammatory agent (BW540C) orally and half received a placebo treatment. BW540C inhibited platelet cyclo-oxygenase for 24 h but the reductions in exudate eicosanoid concentrations were less pronounced. A significant suppression in the rise of surface skin temperature in BW540C-treated ponies paralleled drug-induced inhibition of thromboxane B2 bicyclic prostaglandin (PG) E2 concentrations at the inflamed site. The drug had no significant effect on 6-keto-PGF1 alpha, migrating leucocytes, lactate dehydrogenase or total protein in exudates. Maximum plasma concentrations of both compounds occurred 2 to 4 h after dosing and maximum exudate levels of drug and metabolite occurred at 12 h. Both compounds penetrated approximately three times less readily into exudate than into plasma.
Publication Date: 1987-01-01 PubMed ID: 3691462DOI: 10.1111/j.2042-3306.1987.tb02584.xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
- Research Support
- Non-U.S. Gov't
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
This study investigates the effects of a new non-steroidal anti-inflammatory drug named BW540C on inflammation in horses. The drug was found to reduce inflammation and skin temperature but had no significant effect on various other factors.
Research Method
- In the research, a two-part cross-over experiment was carried out on six ponies.
- Each pony had a small tissue cage implanted under their skin and this was inflamed using a carrageenin injection. Carrageenin is often used to create inflammation for medical testing.
- In each part of the experiment, some ponies received the anti-inflammatory drug, and the others were given a placebo. This allowed the researchers to directly compare the effects of the BW540C drug against the placebo.
Findings
- The study found that the drug inhibits platelet cyclo-oxygenase for 24 hours. This is significant because platelets and cyclo-oxygenase play a key role in the body’s response to inflammation.
- However, the drug’s ability to reduce concentrations of prostaglandins (hormone-like substances that are involved in dealing with injury and illness) was less pronounced.
- A significant result of the study was that BW540C successfully suppressed the rise of surface skin temperature around the inflamed site. This is a key symptom of inflammation.
- Interestingly, the drug did not have any significant effect on other factors related to inflammation such as migrating leukocytes (white blood cells), lactate dehydrogenase (a type of enzyme), or total protein in fluid leaking from the inflamed tissue.
Plasma Concentrations and Penetration
- The study also investigated how the drug and its metabolite (a substance necessary for metabolism) behaved in the body.
- It was found that the maximum plasma concentrations of both the drug and its metabolite occurred between 2 to 4 hours after being given to the ponies.
- It took longer for maximum levels of the drug and metabolite to be observed in the fluid leaking from the inflamed area, with this happening at 12 hours after drug administration.
- Additionally, the report notes that the drug and its metabolite were approximately three times less likely to penetrate into the inflamed area than into the plasma.
Cite This Article
APA
Higgins AJ, Lees P, Sedgwick AD, Buick AR, Churchus R.
(1987).
Use of a novel non-steroidal anti-inflammatory drug in the horse.
Equine Vet J, 19(1), 60-66.
https://doi.org/10.1111/j.2042-3306.1987.tb02584.x Publication
Researcher Affiliations
- Royal Veterinary College, North Mymms, Hatfield, Hertfordshire.
MeSH Terms
- Animals
- Anti-Inflammatory Agents, Non-Steroidal / pharmacokinetics
- Anti-Inflammatory Agents, Non-Steroidal / pharmacology
- Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
- Exudates and Transudates / analysis
- Exudates and Transudates / drug effects
- Female
- Horse Diseases / drug therapy
- Horses / metabolism
- Inflammation / drug therapy
- Inflammation / veterinary
- L-Lactate Dehydrogenase / analysis
- Leukocyte Count / veterinary
- Male
- Pyrazoles / pharmacokinetics
- Pyrazoles / pharmacology
- Pyrazoles / therapeutic use
- Thromboxane B2 / analysis
Citations
This article has been cited 1 times.- Lees P. Pharmacology of drugs used to treat osteoarthritis in veterinary practice.. Inflammopharmacology 2003;11(4):385-99.
Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
